NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01949311,Open-label Study of Dupilumab in Patients With Atopic Dermatitis,https://clinicaltrials.gov/study/NCT01949311,,COMPLETED,"The primary objective is to assess the long-term safety of dupilumab administered in adult participants with atopic dermatitis (AD).

The secondary objective of the study is to assess the immunogenicity of dupilumab in adult participants with AD, in the context of re-treatment, and to monitor efficacy parameters associated with long-term treatment.

Optional Sub-Study:

The primary objective of the sub-study is to assess the safety of the new dupilumab drug product in adult patients with AD after switching from the current dupilumab drug product.

The secondary objectives of the sub-study are to evaluate systemic exposure and immunogenicity of the new dupilumab drug product in adult patients with AD.",YES,Atopic Dermatitis,DRUG: Dupilumab,"Number of Treatment Emergent Adverse Events (TEAEs), Up to 272 weeks|OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug Product, Adverse events of special interest in this study include: Anaphylactic reactions, Systemic hypersensitivity reactions, Helminthic infections, Any severe type of conjunctivitis or blepharitis, Keratitis, Clinically symptomatic eosinophilia (or eosinophilia associated with clinical symptoms), Up to 24 Weeks","Number of Serious Adverse Events (SAEs) of Special Interest, Adverse events of special interest in this study include: Anaphylactic reactions, Systemic hypersensitivity reactions, Helminthic infections, Any severe type of conjunctivitis or blepharitis, Keratitis, Clinically symptomatic eosinophilia (or eosinophilia associated with clinical symptoms), Up to 272 weeks|Rate of AESIs, Rate (events per patient-year) of AESIs

Adverse events of special interest in this study include: Anaphylactic reactions, Systemic hypersensitivity reactions, Helminthic infections, Any severe type of conjunctivitis or blepharitis, Keratitis, Clinically symptomatic eosinophilia (or eosinophilia associated with clinical symptoms), Up to 272 weeks|Number of AESIs, Adverse events of special interest in this study include: Anaphylactic reactions, Systemic hypersensitivity reactions, Helminthic infections, Any severe type of conjunctivitis or blepharitis, Keratitis, Clinically symptomatic eosinophilia (or eosinophilia associated with clinical symptoms), Up to 272 weeks|Percentage of Participants With Investigator's Global Assessment (IGA) Score = 0-1 at Each Visit, IGA is an assessment scale used to determine severity of hand and foot AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration., Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)|Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (≥75% Reduction in EASI Scores From Baseline of the Parent Study) at Each Visit, The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD., Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)""|Percentage of Participants With Low Disease Activity State (eg, IGA ≤2) at Each Visit, Low disease activity state is defined as an IGA score of ≤2 \[mild = 2, almost clear = 1, or clear = 0\], Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)""|Change From Baseline in EASI Score at Each Visit, The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD., Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)""|Percent Change From Baseline in EASI Score at Each Visit, The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD., Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)""|Percentage of Participants With EASI-50 (≥50% Reduction in EASI Scores From Baseline of the Parent Study) at Each Visit, EASI-50 was defined as \>=50% reduction in EASI scores from baseline of the parent study, Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)""|Percentage of Participants With EASI-90 (≥90% Reduction in EASI Scores From Baseline of the Parent Study) at Each Visit, EASI-90 was defined as \>=90% reduction in EASI scores from baseline of the parent study, Up to 272 weeks (End of Study), ""Baseline, Weeks 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 272 (End of Study)""|Change From Baseline in Pruritus Numerical Rating Scale (NRS) in Parent Study, The Pruritus NRS is an assessment tool for patients to report the intensity of their pruritus (itch), using a scale from 0-10, where 0 is no itch and 10 is the worst itch imaginable.

Daily peak pruritus NRS score is the worst one between morning and evening scores of the day. Baseline Pruritus NRS is determined based on average of daily peak NRS scores during the 7 days immediately preceding randomization. A minimum of 4 daily scores out of 7 days is required to calculate baseline average score.

Weekly worst score is calculated by taking the worst score within the week, Up to 272 weeks (End of Study), ""Baseline, Weeks 1, 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 252, 272 (End of Study)""|Percent Change From Baseline in Pruritus NRS, The Pruritus NRS is an assessment tool for patients to report the intensity of their pruritus (itch), using a scale from 0-10, where 0 is no itch and 10 is the worst itch imaginable.

Daily peak pruritus NRS score is the worst one between morning and evening scores of the day. Baseline Pruritus NRS is determined based on average of daily peak NRS scores during the 7 days immediately preceding randomization. A minimum of 4 daily scores out of 7 days is required to calculate baseline average score.

Weekly worst score is calculated by taking the worst score within the week, Up to 272 weeks (End of Study), ""Baseline, Weeks 1, 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 252, 272 (End of Study)""|Percentage of Participants With Improvement (Reduction) of Pruritus NRS ≥3 From Baseline, The Pruritus NRS is an assessment tool for patients to report the intensity of their pruritus (itch), using a scale from 0-10, where 0 is no itch and 10 is the worst itch imaginable.

Daily peak pruritus NRS score is the worst one between morning and evening scores of the day. Baseline Pruritus NRS is determined based on average of daily peak NRS scores during the 7 days immediately preceding randomization. A minimum of 4 daily scores out of 7 days is required to calculate baseline average score.

Weekly worst score is calculated by taking the worst score within the week, Up to 272 weeks (End of Study), ""Baseline, Weeks 1, 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 252, 272 (End of Study)""|Percentage of Participants With Improvement (Reduction) of Pruritus NRS ≥4 From Baseline, The Pruritus NRS is an assessment tool for patients to report the intensity of their pruritus (itch), using a scale from 0-10, where 0 is no itch and 10 is the worst itch imaginable.

Daily peak pruritus NRS score is the worst one between morning and evening scores of the day. Baseline Pruritus NRS is determined based on average of daily peak NRS scores during the 7 days immediately preceding randomization. A minimum of 4 daily scores out of 7 days is required to calculate baseline average score.

Weekly worst score is calculated by taking the worst score within the week, Up to 272 weeks (End of Study), ""Baseline, Weeks 1, 4, 16, 36, 52, 100, 124, 156, 172, 188, 204, 220, 236, 252, 272 (End of Study)""|Percentage of Participants Requiring Rescue Treatment: Overall, Up to 272 weeks|Percentage of Participants Requiring Rescue Treatment: Systemic Treatment, Up to 272 weeks|Percentage of Participants Requiring Rescue Treatment: Phototherapy, Up to 272 weeks|Changes From Current Study Baseline to Prespecified Time Points Through the End of the Study: Dermatology Life Quality Index (DLQI), The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The format is a simple response to 10 items, which assess QOL over the past week, with an overall scoring system of 0 to 30; a high score is indicative of a poor QOL, Up to 272 weeks (End of Study), ""Baseline, Weeks 12, 24, 36, 48, 76, 100, 124, 148, 272 (End of Study)""|Changes From Current Study Baseline to Prespecified Time Points Through the End of the Study: Patient Oriented Eczema Measure (POEM), The POEM is a 7-item, validated questionnaire used in clinical practice and clinical trials to assess disease symptoms in children and adults. The format is a response to 7 items (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) with a scoring system of 0 to 28; a high score is indicative of a poor QOL., Up to 272 weeks (End of Study), ""Baseline, Weeks 12, 24, 36, 48, 76, 100, 124, 148, 272 (End of Study)""|Changes From Parent Study Baseline to Prespecified Time Points Through the End of the Study: EuroQol-5D (EQ-5D), The EuroQOL 5-Dimension Health Questionnaire (EQ-5D) is a standardized measure of health status developed by the EuroQOL Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The minimum value for the single index utility score is -0.594 (Best imaginable health state) and the maximum value for the single index utility score is 1 (Worst imaginable health state)., Up to 272 weeks (End of Study), ""Baseline, Weeks 12, 24, 36, 48, 76, 100, 124, 148, 272 (End of Study)""|OPTIONAL SUB-STUDY: Ctrough of Functional Dupilumab in Serum Before and After Switching to the New Dupilumab Drug Product, Up to week 12|OPTIONAL SUB-STUDY: Incidence of Treatment-emergent Anti-drug Antibody (ADA) Response in Patients Receiving the New Dupilumab Drug Product, For participants receiving dupilumab from a new manufacturing process, ADA baseline was defined as the baseline visit in the sub-study, or at the end of the main study, dependent on available data., Up to 24 Weeks",,Regeneron Pharmaceuticals,Sanofi,ALL,"ADULT, OLDER_ADULT",PHASE3,2733,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,R668-AD-1225|2013-001449-15,2013-10-10,2022-06-27,2022-06-27,2013-09-24,2023-06-23,2023-10-17,"Regeneron Study Site, Anniston, Alabama, 36207, United States|Regeneron Study Site, Birmingham, Alabama, 35205, United States|Regeneron Study Site 1, Birmingham, Alabama, 35209, United States|Regeneron Study Site 2, Birmingham, Alabama, 35233, United States|Regeneron Study Site 2, Phoenix, Arizona, 85018, United States|Regeneron Study Site 3, Phoenix, Arizona, 85023, United States|Regeneron Study Site 1, Phoenix, Arizona, 85032, United States|Regeneron Study Site, Fort Smith, Arkansas, 72916, United States|Regeneron Study Site, Rogers, Arkansas, 72758, United States|Regeneron Study Site, Bakersfield, California, 93309, United States|Regeneron Study Site, Clovis, California, 93612, United States|Regeneron Study Site, Costa Mesa, California, 92626, United States|Regeneron Study Site, Encinitas, California, 92024, United States|Regeneron Study Site, Fremont, California, 94538, United States|Regeneron Study Site, Lomita, California, 90717, United States|Regeneron Study Site, Long Beach, California, 90808, United States|Regeneron Study Site 1, Los Angeles, California, 90025, United States|Regeneron Study Site 2, Los Angeles, California, 90025, United States|Regeneron Study Site, Los Angeles, California, 90045, United States|Regeneron Study Site, Oceanside, California, 92056, United States|Regeneron Study Site, Orange, California, 92868, United States|Regeneron Study Site, Rolling Hills Estates, California, 90274, United States|Regeneron Study Site, San Diego, California, 92122, United States|Regeneron Study Site 1, San Diego, California, 92123, United States|Regeneron Study Site 2, San Diego, California, 92123, United States|Regeneron Study Site, Santa Monica, California, 90404, United States|Regeneron Study Site, Centennial, Colorado, 80112, United States|Regeneron Study Site, Denver, Colorado, 80206, United States|Regeneron Study Site, Denver, Colorado, 80220, United States|Regeneron Study Site, Trumbull, Connecticut, 06611, United States|Regeneron Study Site, Washington, District of Columbia, 20037, United States|Regeneron Study Site, Boca Raton, Florida, 33486, United States|Regeneron Study Site, Clearwater, Florida, 33756, United States|Regeneron Study Site, Fort Lauderdale, Florida, 33306, United States|Regeneron Study Site 1, Jacksonville, Florida, 32216, United States|Regeneron Study Site 2, Jacksonville, Florida, 32216, United States|Regeneron Study Site, Lake Worth, Florida, 33461, United States|Regeneron Study Site, Miami Lakes, Florida, 33016, United States|Regeneron Study Site, Miami, Florida, 33135, United States|Regeneron Study Site, Miami, Florida, 33144, United States|Regeneron Study Site, Orlando, Florida, 32806, United States|Regeneron Study Site, Tampa, Florida, 33607, United States|Regeneron Study Site, Tampa, Florida, 33614, United States|Regeneron Study Site, Tampa, Florida, 33624, United States|Regeneron Study Site, West Palm Beach, Florida, 33406, United States|Regeneron Study Site, Alpharetta, Georgia, 30022, United States|Regeneron Study Site, Atlanta, Georgia, 30322, United States|Regeneron Study Site, Columbus, Georgia, 31904, United States|Regeneron Study Site, Macon, Georgia, 31217, United States|Regeneron Study Site, Newnan, Georgia, 30263, United States|Regeneron Study Site, Sandy Springs, Georgia, 30328, United States|Regeneron Study Site, Savannah, Georgia, 31405, United States|Regeneron Study Site, Chicago, Illinois, 60611, United States|Regeneron Study Site, Normal, Illinois, 61761, United States|Regeneron Study Site, West Dundee, Illinois, 60118, United States|Regeneron Study Site, Indianapolis, Indiana, 46250, United States|Regeneron Study Site, Newburgh, Indiana, 47630, United States|Regeneron Study Site, Plainfield, Indiana, 46168, United States|Regeneron Study Site, Overland Park, Kansas, 66215, United States|Regeneron Study Site, New Orleans, Louisiana, 70112, United States|Regeneron Study Site, Rockville, Maryland, 20850, United States|Regeneron Study Site, Boston, Massachusetts, 02111, United States|Regeneron Study Site, Boston, Massachusetts, 02114, United States|Regeneron Study Site, Boston, Massachusetts, 02115, United States|Regeneron Study Site, Bay City, Michigan, 48706, United States|Regeneron Study Site, Farmington Hills, Michigan, 48334, United States|Regeneron Study Site, Troy, Michigan, 48084, United States|Regeneron Study Site, Edina, Minnesota, 55435, United States|Regeneron Study Site, Fridley, Minnesota, 55432, United States|Regeneron Study Site, Minneapolis, Minnesota, 55402, United States|Regeneron Study Site, Plymouth, Minnesota, 55402, United States|Regeneron Study Site, Saint Joseph, Missouri, 64506, United States|Regeneron Study Site, Saint Louis, Missouri, 63104, United States|Regeneron Study Site, Saint Louis, Missouri, 63141, United States|Regeneron Study Site, Henderson, Nevada, 89052, United States|Regeneron Study Site, Las Vegas, Nevada, 89119, United States|Regeneron Study Site, Portsmouth, New Hampshire, 03801, United States|Regeneron Study Site, Berlin, New Jersey, 08009, United States|Regeneron Study Site, East Windsor, New Jersey, 08520, United States|Regeneron Study Site, Verona, New Jersey, 07044-2946, United States|Regeneron Study Site 1, Albuquerque, New Mexico, 87106, United States|Regeneron Study Site 2, Albuquerque, New Mexico, 87106, United States|Regeneron Study Site, Buffalo, New York, 14203, United States|Regeneron Study Site, Corning, New York, 14830, United States|Regeneron Study Site, Forest Hills, New York, 11375, United States|Regeneron Study Site, New York, New York, 10016, United States|Regeneron Study Site, New York, New York, 10021, United States|Regeneron Study Site, New York, New York, 10029-6501, United States|Regeneron Study Site, New York, New York, 10075, United States|Regeneron Study Site, Rochester, New York, 14642, United States|Regeneron Study Site, Chapel Hill, North Carolina, 27516, United States|Regeneron Study Site, High Point, North Carolina, 27262, United States|Regeneron Study Site, Raleigh, North Carolina, 27612, United States|Regeneron Study Site, Wilmington, North Carolina, 28405, United States|Regeneron Study Site, Winston-Salem, North Carolina, 27104, United States|Regeneron Study Site, Cincinnati, Ohio, 45231, United States|Regeneron Study Site, Cleveland, Ohio, 44106, United States|Regeneron Study Site, Norman, Oklahoma, 73071, United States|Regeneron Study Site, Tulsa, Oklahoma, 74136, United States|Regeneron Study Site, Medford, Oregon, 97504-9741, United States|Regeneron Study Site, Portland, Oregon, 97223, United States|Regeneron Study Site, Portland, Oregon, 97239, United States|Regeneron Study Site, Bethlehem, Pennsylvania, 18020, United States|Regeneron Study Site, Jenkintown, Pennsylvania, 19046, United States|Regeneron Study Site, Philadelphia, Pennsylvania, 19104, United States|Regeneron Study Site, Pittsburgh, Pennsylvania, 15213, United States|Regeneron Study Site, Charleston, South Carolina, 29407, United States|Regeneron Study Site, Greer, South Carolina, 29650, United States|Regeneron Study Site, Chattanooga, Tennessee, 37421, United States|Regeneron Study Site, Nashville, Tennessee, 37215, United States|Regeneron Study Site, Arlington, Texas, 76011, United States|Regeneron Study Site, Austin, Texas, 78705, United States|Regeneron Study Site, Bellaire, Texas, 77401-3505, United States|Regeneron Study Site, Dallas, Texas, 75230, United States|Regeneron Study Site, Dallas, Texas, 75231, United States|Regeneron Study Site, Dallas, Texas, 75246, United States|Regeneron Study Site, Houston, Texas, 77004, United States|Regeneron Study Site, San Antonio, Texas, 78218, United States|Regeneron Study Site 1, San Antonio, Texas, 78229, United States|Regeneron Study Site 2, San Antonio, Texas, 78229, United States|Regeneron Study Site, San Antonio, Texas, 78258, United States|Regeneron Study Site, Waco, Texas, 76710, United States|Regeneron Study Site, Webster, Texas, 77598, United States|Regeneron Study Site, Salt Lake City, Utah, 84132, United States|Regeneron Study Site, South Burlington, Vermont, 05403, United States|Regeneron Study Site, Newport News, Virginia, 23606-4537, United States|Regeneron Study Site, Norfolk, Virginia, 23502, United States|Regeneron Study Site, Richmond, Virginia, 23220, United States|Regeneron Study Site, Seattle, Washington, 98101, United States|Regeneron Study Site, Phillip, Australian Capital Territory, Australia|Regeneron Study Site, Kogarah, New South Wales, Australia|Regeneron Study Site, Benowa, Queensland, Australia|Regeneron Study Site, Woolloongabba, Queensland, Australia|Regeneron Study Site, Hectorville, South Australia, Australia|Regeneron Study Site, Carlton, Victoria, Australia|Regeneron Study Site, East Melbourne, Victoria, Australia|Regeneron Study Site, Fremantle, Western Australia, Australia|Regeneron Study Site 1, Wien, Austria|Regeneron Study Site 2, Wien, Austria|Regeneron Study Site, Bruxelles, Brussels Capital Region, Belgium|Regeneron Study Site, Loverval, Hainaut, Belgium|Regeneron Study Site, Leuven, Vlaams Brabant, Belgium|Regeneron Study Site, Dupnitsa, Kjustendil, Bulgaria|Regeneron Study Site 1, Sofia, Sofia-Grad, Bulgaria|Regeneron Study Site 2, Sofia, Sofia-Grad, Bulgaria|Regeneron Study Site 1, Calgary, Alberta, Canada|Regeneron Study Site 2, Calgary, Alberta, Canada|Regeneron Study Site 1, Edmonton, Alberta, Canada|Regeneron Study Site 2, Edmonton, Alberta, Canada|Regeneron Study Site 1, Surrey, British Columbia, Canada|Regeneron Study Site 2, Surrey, British Columbia, Canada|Regeneron Study Site 1, Vancouver, British Columbia, Canada|Regeneron Study Site 2, Vancouver, British Columbia, Canada|Regeneron Study Site 3, Vancouver, British Columbia, Canada|Regeneron Study Site 1, Winnipeg, Manitoba, Canada|Regeneron Study Site, Bathurst, New Brunswick, Canada|Regeneron Study Site, St. John's, Newfoundland and Labrador, Canada|Regeneron Study Site, Ajax, Ontario, Canada|Regeneron Study Site 1, Barrie, Ontario, Canada|Regeneron Study Site 2, Barrie, Ontario, Canada|Regeneron Study Site, Etobicoke, Ontario, Canada|Regeneron Study Site 1, Hamilton, Ontario, Canada|Regeneron Study Site 2, Hamilton, Ontario, Canada|Regeneron Study Site, Markham, Ontario, Canada|Regeneron Study Site, Mississauga, Ontario, Canada|Regeneron Study Site, Newmarket, Ontario, Canada|Regeneron Study Site, North Bay, Ontario, Canada|Regeneron Study Site, Oakville, Ontario, Canada|Regeneron Study Site 1, Ottawa, Ontario, Canada|Regeneron Study Site, Peterborough, Ontario, Canada|Regeneron Study Site 1, Richmond Hill, Ontario, Canada|Regeneron Study Site 2, Richmond Hill, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Waterloo, Ontario, Canada|Regeneron Study Site 1, Windsor, Ontario, Canada|Regeneron Study Site 2, Windsor, Ontario, Canada|Regeneron Study Site, Drummondville, Quebec, Canada|Regeneron Study Site, Montreal, Quebec, Canada|Regeneron Study Site 3, Ste-Foy, Quebec, Canada|Regeneron Study Site, Ste-Foy, Canada|Regeneron Study Site, Winnipeg, Canada|Regeneron Study Site, Hong Kong, China|Regeneron Study Site, Hradec Kralove, Czechia|Regeneron Study Site, Kutna Hora, Czechia|Regeneron Study Site, Nachod, Czechia|Regeneron Study Site, Praha 10, Czechia|Regeneron Study Site, Praha 5, Czechia|Regeneron Study Site, Praha 6, Czechia|Regeneron Study Site, Svitavy, Czechia|Regeneron Study Site, Usti nad Labem, Czechia|Regeneron Study Site, Copenhagen, Capital, Denmark|Regeneron Study Site, Hellerup, Capital, Denmark|Regeneron Study Site, Aarhus, Central Jutland, Denmark|Regeneron Study Site, Roskilde, Zeeland, Denmark|Regeneron Study Site 1, Tallinn, Harjumaa, Estonia|Regeneron Study Site 2, Tallinn, Harjumaa, Estonia|Regeneron Study Site 3, Tallinn, Harjumaa, Estonia|Regeneron Study Site 1, Tartu, Tartumaa, Estonia|Regeneron Study Site 2, Tartu, Tartumaa, Estonia|Regeneron Study Site, Helsinki, Etelä-Suomen Iääni, Finland|Regeneron Study Site, Turku, Etelä-Suomen Lääni, Finland|Regeneron Study Site, Tampere, Länsi-Suomen Lääni, Finland|Regeneron Study Site, Nice Cedex 3, Alpes-Maritimes, France|Regeneron Study Site, Marseille, Bouches-du-Rhône, France|Regeneron Study Site, Reims, Marne, France|Regeneron Study Site, Lille, Nord, France|Regeneron Study Site, Pierre Benite, Rhône-Alpes, France|Regeneron Study Site, Lille cedex, France|Regeneron Study Site, Nantes, France|Regeneron Study Site, Paris, Île-de-France, France|Regeneron Study Site, Friedrichshafen, Baden-Württemberg, Germany|Regeneron Study Site, Heidelberg, Baden-Württemberg, Germany|Regeneron Study Site, Langenau, Baden-Württemberg, Germany|Regeneron Study Site, Stuttgart, Baden-Württemberg, Germany|Regeneron Study Site, Tuebingen, Baden-Württemberg, Germany|Regeneron Study Site, Augsburg, Bayern, Germany|Regeneron Study Site, Erlangen, Bayern, Germany|Regeneron Study Site, Munchen, Bayern, Germany|Regeneron Study Site, Munich, Bayern, Germany|Regeneron Study Site, Mahlow, Brandenburg, Germany|Regeneron Study Site 2, Hamburg, Hamburgh, Germany|Regeneron Study Site, Frankfurt/Main, Hessen, Germany|Regeneron Study Site, Schwerin, Mecklenburg-Vorpommern, Germany|Regeneron Study Site, Hannover, Niedersachsen, Germany|Regeneron Study Site 1, Bochum, Nordrhein-Westfalen, Germany|Regeneron Study Site 2, Bochum, Nordrhein-Westfalen, Germany|Regeneron Study Site, Dulmen, Nordrhein-Westfalen, Germany|Regeneron Study Site, Ibbenbüren, Nordrhein-Westfalen, Germany|Regeneron Study Site, Monchengladbach, Nordrhein-Westfalen, Germany|Regeneron Study Site, Muenster, Nordrhein-Westfalen, Germany|Regeneron Study Site, Mainz, Rheinland-Pfalz, Germany|Regeneron Study Site, Selters, Rheinland-Pfalz, Germany|Regeneron Study Site, Halle, Sachsen-Anhalt, Germany|Regeneron Study Site, Magdeburg, Sachsen-Anhalt, Germany|Regeneron Study Site 1, Dresden, Sachsen, Germany|Regeneron Study Site 2, Dresden, Sachsen, Germany|Regeneron Study Site 3, Dresden, Sachsen, Germany|Regeneron Study Site, Leipzig, Sachsen, Germany|Regeneron Study Site 1, Kiel, Schleswig-Holstein, Germany|Regeneron Study Site 2, Kiel, Schleswig-Holstein, Germany|Regeneron Study Site, Lubeck, Schleswig-Holstein, Germany|Regeneron Study Site, Gera, Thüringen, Germany|Regeneron Study Site 1, Berlin, Germany|Regeneron Study Site 2, Berlin, Germany|Regeneron Study Site 3, Berlin, Germany|Regeneron Study Site 4, Berlin, Germany|Regeneron Study Site 5, Berlin, Germany|Regeneron Study Site 6, Berlin, Germany|Regeneron Study Site 7, Berlin, Germany|Regeneron Study Site, Bonn, Germany|Regeneron Study Site, Darmstadt, Germany|Regeneron Study Site 1, Hamburg, Germany|Regeneron Study Site, Münster, Germany|Regeneron Study Site, Osnabrück, Germany|Regeneron Study Site, Sátoraljaújhely, Borsod-Abaúj-Zemplén, Hungary|Regeneron Study Site, Oroshaza, Békés, Hungary|Regeneron Study Site, Szeged, Csongrád, Hungary|Regeneron Study Site, Szolnok, Jász-Nagykun-Szolnok, Hungary|Regeneron Study Site, Kaposvár, Somogy, Hungary|Regeneron Study Site 1, Budapest, Hungary|Regeneron Study Site 2, Budapest, Hungary|Regeneron Study Site 3, Budapest, Hungary|Regeneron Study Site, Veszprem, Hungary|Regeneron Study Site, Dublin, Ireland|Regeneron Study Site, Bologna, Balogna, Italy|Regeneron Study Site, Ancona, Italy|Regeneron Study Site, Chieti, Italy|Regeneron Study Site, Firenze, Italy|Regeneron Study Site, L'Aquila, Italy|Regeneron Study Site, Lucca, Italy|Regeneron Study Site, Messina, Italy|Regeneron Study Site, Milano, Italy|Regeneron Study Site, Novara, Italy|Regeneron Study Site, Pavia, Italy|Regeneron Study Site, Perugia, Italy|Regeneron Study Site, Pisa, Italy|Regeneron Study Site 1, Roma, Italy|Regeneron Study Site 2, Roma, Italy|Regeneron Study Site, Nagakute, Aichi, Japan|Regeneron Study Site, Kurume, Fukuoka, Japan|Regeneron Study Site, Fukuyama, Hiroshima, Japan|Regeneron Study Site, Sapporo, Hokkaido, Japan|Regeneron Study Site 1, Fukuoka, Hukuoka, Japan|Regeneron Study Site 2, Fukuoka, Hukuoka, Japan|Regeneron Study Site, Kitakyushu, Hukuoka, Japan|Regeneron Study Site 1, Amagasaki, Hyôgo, Japan|Regeneron Study Site 2, Amagasaki, Hyôgo, Japan|Regeneron Study Site, Inashiki-gun, Ibaraki, Japan|Regeneron Study Site 1, Yokohama, Kanagawa, Japan|Regeneron Study Site 2, Yokohama, Kanagawa, Japan|Regeneron Study Site 3, Yokohama, Kanagawa, Japan|Regeneron Study Site, Kamimashiki, Kumamoto, Japan|Regeneron Study Site, Habikino, Osaka, Japan|Regeneron Study Site, Neyagawa, Osaka, Japan|Regeneron Study Site, Sakai, Osaka, Japan|Regeneron Study Site, Takatsuki, Osaka, Japan|Regeneron Study Site, Hamamatsu, Shizuoka, Japan|Regeneron Study Site, Yaizu, Shizuoka, Japan|Regeneron Study Site 1, Bunkyo-ku, Tokyo, Japan|Regeneron Study Site 2, Bunkyo-ku, Tokyo, Japan|Regeneron Study Site 1, Chiyoda-ku, Tokyo, Japan|Regeneron Study Site 2, Chiyoda-ku, Tokyo, Japan|Regeneron Study Site, Chuo-ku, Tokyo, Japan|Regeneron Study Site, Koto-ku, Tokyo, Japan|Regeneron Study Site, Nakano-ku, Tokyo, Japan|Regeneron Study Site 1, Nerima, Tokyo, Japan|Regeneron Study Site 2, Nerima, Tokyo, Japan|Regeneron Study Site, Ota-ku, Tokyo, Japan|Regeneron Study Site, Setagaya-ku, Tokyo, Japan|Regeneron Study Site 1, Shibuya-ku, Tokyo, Japan|Regeneron Study Site 2, Shibuya-ku, Tokyo, Japan|Regeneron Study Site 3, Shibuya-ku, Tokyo, Japan|Regeneron Study Site 1, Shinagawa-ku, Tokyo, Japan|Regeneron Study Site 2, Shinagawa-ku, Tokyo, Japan|Regeneron Study Site 1, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 2, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 3, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 4, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 5, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 6, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 1, Suginami, Tokyo, Japan|Regeneron Study Site 2, Suginami, Tokyo, Japan|Regeneron Study Site, Kofu, Yamanashi, Japan|Regeneron Study Site, Chuo, Yamanasi, Japan|Regeneron Study Site 2, Fukuyama, Japan|Regeneron Study Site, Gifu, Japan|Regeneron Study Site 1, Hiroshima, Japan|Regeneron Study Site 2, Hiroshima, Japan|Regeneron Study Site 1, Kyoto, Japan|Regeneron Study Site 2, Kyoto, Japan|Regeneron Study Site 1, Osaka, Japan|Regeneron Study Site 2, Osaka, Japan|Regeneron Study Site, Saitama, Japan|Regeneron Study Site 3, Shinagawa-ku, Japan|Regeneron Study Site, Suginome, Japan|Regeneron Study Site, Wakayama, Japan|Regeneron Study Site 4, Yokohama, Japan|Regeneron Study Site, Busan, Busan Gwang'yeogsi, Korea, Republic of|Regeneron Study Site, Bucheon-Si, Kyonggi-do, Korea, Republic of|Regeneron Study Site, Hwaseong-si, Kyonggi-do, Korea, Republic of|Regeneron Study Site, Suwon, Kyonggi-do, Korea, Republic of|Regeneron Study Site, Uijeongbu-si, Kyonggi-do, Korea, Republic of|Regeneron Study Site 1, Incheon, Korea, Republic of|Regeneron Study Site 2, Incheon, Korea, Republic of|Regeneron Study Site 1, Seoul, Korea, Republic of|Regeneron Study Site 2, Seoul, Korea, Republic of|Regeneron Study Site 3, Seoul, Korea, Republic of|Regeneron Study Site 4, Seoul, Korea, Republic of|Regeneron Study Site 5, Seoul, Korea, Republic of|Regeneron Study Site 6, Seoul, Korea, Republic of|Regeneron Study Site 7, Seoul, Korea, Republic of|Regeneron Study Site 8, Seoul, Korea, Republic of|Regeneron Study Site, Kaunas, Kauno Apskritis, Lithuania|Regeneron Study Site 1, Vilnius, Vilniaus Apskritis, Lithuania|Regeneron Study Site 2, Vilnius, Vilniaus Apskritis, Lithuania|Regeneron Study Site 1, Klaipeda, Lithuania|Regeneron Study Site 2, Klaipeda, Lithuania|Regeneron Study Site, Breda, Noord-Brabant, Netherlands|Regeneron Study Site, Amsterdam, Noord-Holland, Netherlands|Regeneron Study Site, Rotterdam, Zuid-Holland, Netherlands|Regeneron Study Site, Groningen, Netherlands|Regeneron Study Site, Utrecht, Netherlands|Regeneron Study Site, Dunedin, South Island, New Zealand|Regeneron Study Site, Auckland, New Zealand|Regeneron Study Site 1, Wroclaw, Dolnośląskie, Poland|Regeneron Study Site 2, Wroclaw, Dolnośląskie, Poland|Regeneron Study Site 3, Wroclaw, Dolnośląskie, Poland|Regeneron Study Site, Torun, Kujawsko-pomorskie, Poland|Regeneron Study Site 1, Lodz, Lodzkie, Poland|Regeneron Study Site 2, Lodz, Lodzkie, Poland|Regeneron Study Site 3, Lodz, Lodzkie, Poland|Regeneron Study Site, Lublin, Lubelskie, Poland|Regeneron Study Site 1, Krakow, Malopolskie, Poland|Regeneron Study Site 2, Krakow, Malopolskie, Poland|Regeneron Study Site 3, Krakow, Malopolskie, Poland|Regeneron Study Site 1, Warszawa, Mazowieckie, Poland|Regeneron Study Site 2, Warszawa, Mazowieckie, Poland|Regeneron Study Site 3, Warszawa, Mazowieckie, Poland|Regeneron Study Site 4, Warszawa, Mazowieckie, Poland|Regeneron Study Site 5, Warszawa, Mazowieckie, Poland|Regeneron Study Site 6, Warszawa, Mazowieckie, Poland|Regeneron Study Site 7, Warszawa, Mazowieckie, Poland|Regeneron Study Site, Strzelce Opolskie, Opolskie, Poland|Regeneron Study Site, Iwonicz Zdroj, Podkarpackie, Poland|Regeneron Study Site 1, Gdansk, Pomorskie, Poland|Regeneron Study Site 2, Gdansk, Pomorskie, Poland|Regeneron Study Site 1, Poznan, Wielkopolskie, Poland|Regeneron Study Site 2, Poznan, Wielkopolskie, Poland|Regeneron Study Site 3, Poznan, Wielkopolskie, Poland|Regeneron Study Site, Szczecin, Zachodniopomorskie, Poland|Regeneron Study Site, Bialystok, Poland|Regeneron Study Site, Bydgoszcz, Poland|Regeneron Study Site, Chorzow, Poland|Regeneron Study Site, Elblag, 82300, Poland|Regeneron Study Site 1, Katowice, Poland|Regeneron Study Site 2, Katowice, Poland|Regeneron Study Site 3, Katowice, Poland|Regeneron Study Site, Ostrowiec Swietokrzyski, Poland|Regeneron Study Site, Skarzysko-Kamienna, Poland|Regeneron Study Site, Zgierz, 95100, Poland|Regeneron Study Site, Brasov, Romania|Regeneron Study Site, Moscow, Koskva, Russian Federation|Regeneron Study Site, Ryazan, Ryazanskaya Oblast', Russian Federation|Regeneron Study Site, Saint Petersburg, Sankt-Peterburg, Russian Federation|Regeneron Study Site, Kazan, Tatarstan Respublika, Russian Federation|Regeneron Study Site, Chelyabinsk, Russian Federation|Regeneron Study Site 1, Singapore, Central Singapore, Singapore|Regeneron Study Site 2, Singapore, Central Singapore, Singapore|Regeneron Study Site, Singapore, South West, Singapore|Regeneron Study Site, Kosice, Slovakia|Regeneron Study Site, Svidnik, Slovakia|Regeneron Study Site, Elche, Alicante, Spain|Regeneron Study Site, Badalona, Barcelona, Spain|Regeneron Study Site, Las Palmas de Gran Canaria, Canarias, Spain|Regeneron Study Site 1, Barcelona, Spain|Regeneron Study Site 2, Barcelona, Spain|Regeneron Study Site 3, Barcelona, Spain|Regeneron Study Site 4, Barcelona, Spain|Regeneron Study Site 1, Madrid, Spain|Regeneron Study Site 2, Madrid, Spain|Regeneron Study Site, Sevilla, Spain|Regeneron Study Site, Dundee, Angus, United Kingdom|Regeneron Study Site, Edgbaston, Birmingham, United Kingdom|Regeneron Study Site, Plymouth, Devon, United Kingdom|Regeneron Study Site, Portsmouth, Hampshire, United Kingdom|Regeneron Study Site, Sidcup, Kent, United Kingdom|Regeneron Study Site, Northwood, London, United Kingdom|Regeneron Study Site, Oxford, Oxfordshire, United Kingdom|Regeneron Study Site, Liverpool, United Kingdom|Regeneron Study Site 1, London, United Kingdom|Regeneron Study Site 2, London, United Kingdom|Regeneron Study Site, Manchester, United Kingdom|Regeneron Study Site, Salford, United Kingdom|Regeneron Study Site, Sheffield, United Kingdom","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/11/NCT01949311/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/11/NCT01949311/SAP_001.pdf"
